2,4- diamino- 5- (2,3- dichlorophenyl)- 6- fluoromethylpyrimidine
an antihyperalgesic agent
Networked: 2
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Neuralgia (Stump Neuralgia)
|
| 2. | Pain (Aches)
06/01/2002
- " 4030W92, at 25 mg/day, produced a nonsignificant reduction in pain without treatment limiting side effects. " 06/01/2002
- " At baseline, postdose day 1, day 7, and day 14, the following were measured: (1) spontaneous and evoked pain scores, (2) dynamic and static allodynia mapping, (3) Short Form McGill Pain Questionnaire, and (4) blood sample for 4030W92 assay. " 06/01/2004
- " Similarly, oral lamotrigine or 4030W92 did not alter the pain scores reported from mechanical pain stimuli at any time postcapsaicin. " 06/01/2004
- " While capsaicin significantly decreased the hot pain and VF pain thresholds, oral lamotrigine and 4030W92 failed to alter this response to capsaicin, relative to placebo treatment. "
|
| 3. | Hyperalgesia
06/01/2002
- " The area of static allodynia was significantly smaller (P = .03) on treatment day 7 for 4030W92 compared to placebo. " 06/01/2002
- " Allodynia severity was significantly lower (P = .046) on treatment day 1, postdose for 4030W92 compared to placebo. " 06/01/2002
- " At baseline, postdose day 1, day 7, and day 14, the following were measured: (1) spontaneous and evoked pain scores, (2) dynamic and static allodynia mapping, (3) Short Form McGill Pain Questionnaire, and (4) blood sample for 4030W92 assay. " 06/01/2004
- " Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model."
|
|
Related Drugs and Biologics